Ardent Health (NYSE:ARDT) Announces Earnings Results

Ardent Health (NYSE:ARDT) announced its earnings results on Wednesday. The company reported $0.32 earnings per share for the quarter, missing the consensus estimate of $0.35 by ($0.03), FiscalAI reports. The firm had revenue of $1.61 billion during the quarter, compared to analysts’ expectations of $1.63 billion. Ardent Health had a net margin of 3.24% and a return on equity of 19.02%. Ardent Health updated its FY 2026 guidance to 0.900-1.270 EPS.

Ardent Health Trading Up 1.9%

Shares of NYSE ARDT opened at $9.59 on Thursday. The company has a quick ratio of 1.95, a current ratio of 2.08 and a debt-to-equity ratio of 0.67. The business has a fifty day simple moving average of $9.00 and a two-hundred day simple moving average of $11.04. The firm has a market cap of $1.37 billion, a PE ratio of 6.61, a price-to-earnings-growth ratio of 5.18 and a beta of 0.46. Ardent Health has a twelve month low of $8.07 and a twelve month high of $15.48.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on the stock. Mizuho reduced their price objective on shares of Ardent Health from $20.00 to $12.00 and set an “outperform” rating on the stock in a research report on Thursday, December 18th. KeyCorp cut Ardent Health from an “overweight” rating to a “sector weight” rating in a research note on Monday, November 17th. Leerink Partners set a $16.00 price target on Ardent Health in a research note on Friday, November 14th. JPMorgan Chase & Co. decreased their price target on Ardent Health from $12.00 to $11.00 and set a “neutral” rating for the company in a research note on Tuesday, January 20th. Finally, Wall Street Zen downgraded Ardent Health from a “buy” rating to a “hold” rating in a research report on Sunday, November 23rd. Six research analysts have rated the stock with a Buy rating, four have given a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $14.58.

Institutional Trading of Ardent Health

Several institutional investors and hedge funds have recently made changes to their positions in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in Ardent Health by 103.8% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 14,104 shares of the company’s stock worth $194,000 after acquiring an additional 7,182 shares during the period. Goldman Sachs Group Inc. raised its holdings in shares of Ardent Health by 1,684.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 767,862 shares of the company’s stock valued at $10,558,000 after purchasing an additional 724,841 shares in the last quarter. Jane Street Group LLC lifted its position in shares of Ardent Health by 235.1% in the 1st quarter. Jane Street Group LLC now owns 57,468 shares of the company’s stock worth $790,000 after purchasing an additional 40,318 shares during the period. Acadian Asset Management LLC lifted its position in shares of Ardent Health by 574.9% in the 1st quarter. Acadian Asset Management LLC now owns 40,238 shares of the company’s stock worth $550,000 after purchasing an additional 34,276 shares during the period. Finally, Geode Capital Management LLC boosted its stake in shares of Ardent Health by 0.6% during the second quarter. Geode Capital Management LLC now owns 286,848 shares of the company’s stock valued at $3,918,000 after purchasing an additional 1,769 shares in the last quarter.

Ardent Health News Roundup

Here are the key news stories impacting Ardent Health this week:

• Neutral Sentiment: Ardent published its Q4 press release and slide deck with results and guidance, allowing investors to review the detailed numbers and management commentary. Press Release
• Negative Sentiment: Q4 results missed estimates: EPS $0.32 vs. consensus $0.35 and revenue $1.61B vs. $1.63B — an earnings/revenue miss that weakens near‑term sentiment. Zacks: Q4 Miss
• Negative Sentiment: FY‑2026 guidance was lowered/updated to EPS $0.90–$1.27 (consensus ~$1.40) and revenue $6.4B–$6.7B (consensus ~$6.7B), signaling weaker outlook and prompting investor re‑rating. Slide Deck / Guidance
• Negative Sentiment: New/renewed legal risk: multiple law firms (Hagens Berman, Schall, Rosen, Pomerantz, others) are filing or soliciting lead‑plaintiff motions and investigating alleged accounting issues (a reported ~$97M adjustment and the “180‑day cliff” reserves). That litigation and investigation pipeline raises potential for material legal/financial exposure and investor uncertainty. GlobeNewswire: Hagens Berman Investigation
• Negative Sentiment: Multiple class‑action notices and March 9 lead‑plaintiff deadlines (numerous firms issuing alerts) amplify media/legal attention and could increase litigation coordination and potential recovery claims against the company and executives. GlobeNewswire: Schall Law Firm

Ardent Health Company Profile

Ardent Health, listed on the New York Stock Exchange under the ticker ARDT, is a healthcare delivery company focused on acquiring, developing and managing acute care hospitals and complementary outpatient facilities across the United States. The company’s integrated platform encompasses both inpatient and outpatient services, designed to provide end-to-end care solutions and address the full continuum of patient needs.

Through its network, Ardent Health operates general hospitals, emergency departments, ambulatory surgery centers, urgent care clinics, rehabilitation and post-acute care facilities.